Disparities in non-small cell lung cancer (NSCLC) treatment based on race, treatment center
the ONA take:
According to new findings published in the Journal of Thoracic Oncology, researchers have found significant disparities for treatment of African American, Hispanic, and community hospital-treated patients for non-small cell lung cancer (NSCLC).
Specifically, those patient populations were found to be less likely than other patients to receive care for early stage non-small cell lung cancer (NSCLC). For the study, researchers identified nearly 40,000 patients with inoperable stage 1 NSCLC from the National Cancer Database between 2003 and 2011.
They found that African Americans and Hispanics were 40% and 60%, respectively, less likely than others to be treated with either conventional radiation or stereotactic body radiotherapy (SBRT), a technique that delivers higher doses of radiation that requires fewer treatments and is better tolerated.. African Americans and patients without insurance were more likely to receive conventional radiation rather than SBRT if they received radiation at all.
In addition, patients treated in academic hospital were 2.5 times more likely to be treated with SBRT compared with those treated in community hospitals. Patients treated at a high-volume medical center were seven times more likely to receive SBRT compared with those treated at a low-volume center.
Significant disparities for treatment of African American, Hispanic, and community hospital-treated patients for NSCLC.
African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology.
“We found significant disparities for treatment of a curable cancer based on race, insurance status, and whether or not treatment was at an academic or community hospital,” said Dr. Matthew Koshy, a physician in the department of radiation oncology at the University of Illinois at Chicago College of Medicine, and lead author of the study.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|